Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Victor H. F. Lee"'
Autor:
Wei Kang, Caige Huang, Vincent K. C. Yan, Yue Wei, Jessica J. P. Shami, Silvia T. H. Li, Yu Yang, Xuxiao Ye, Junhan Tang, Shing Fung Lee, Victor H. F. Lee, Stephen L. Chan, Aya El Helali, Ka On Lam, Roger K. C. Ngan, Ian C. K. Wong, Esther W. Chan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Given the existing uncertainty regarding the effectiveness and safety of switching from low-molecular-weight heparin (LMWH) to direct oral anticoagulants (DOACs) in patients with cancer-associated venous thrombosis (CAT), we conducted a comp
Externí odkaz:
https://doaj.org/article/3266406845e141328a147fcdb5358cb5
Autor:
Shuzhan Li, Wei Dai, Ngar-Woon Kam, Jiali Zhang, Victor H. F. Lee, Xiubao Ren, Dora Lai-Wan Kwong
Publikováno v:
Cancers, Vol 16, Iss 7, p 1312 (2024)
Endemic nasopharyngeal carcinoma (NPC) is closely associated with the Epstein–Barr virus (EBV), which contributes to tumor development and influences the tumor immune microenvironment (TIME) in NPC. Natural killer (NK) cells, as part of the innate
Externí odkaz:
https://doaj.org/article/afe001c6136f4be2934bb025d4bcd30d
Autor:
Wei Kang, Kuan Peng, Vincent K.C. Yan, Daoud Al-Badriyeh, Shing Fung Lee, Hei Hang Edmund Yiu, Yue Wei, Silvia T. H. Li, Xuxiao Ye, Aya El Helali, Ka On Lam, Victor H. F. Lee, Ian C. K. Wong, Esther W. Chan
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 17, Iss 1 (2024)
Background Direct oral anticoagulants (DOACs) have demonstrated clinical benefits and better patient adherence over low-molecular-weight heparin (LMWH) in treating patients with cancer-associated venous thrombosis (CAT). We aimed to compare the cost-
Externí odkaz:
https://doaj.org/article/fc12840ea12043cfa1e40c07e93c83c3
Autor:
Wei Kang, Jessica J. P. Shami, Vincent K. C. Yan, Xuxiao Ye, Joseph E. Blais, Xue Li, Victor H. F. Lee, Celine S. L. Chui, Francisco T. T. Lai, Eric Y. F. Wan, Carlos K. H. Wong, Ian C. K. Wong, Esther W. Chan
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Background The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contr
Externí odkaz:
https://doaj.org/article/8d7ea4c350b54c8db57f62bfd32e0143
Autor:
Shing Fung Lee, Horace C. W. Choi, Sik Kwan Chan, Ka On Lam, Victor H. F. Lee, Irene O. L. Wong, Chi Leung Chiang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesWe aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-lin
Externí odkaz:
https://doaj.org/article/111ed691c06345b4aa7a33edb674f9fd
Autor:
Keith W. H. Chiu, Ka-On Lam, H. An, Gavin T. C. Cheung, Johnny K. S. Lau, Tim-Shing Choy, Victor H. F. Lee
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background 18F-FDG PET-CT is commonly used to monitor treatment response in patients with metastatic colorectal cancer (mCRC). With improvement in systemic therapy, complete metabolic response (CMR) is increasingly encountered but its clinic
Externí odkaz:
https://doaj.org/article/60f63ed2b18d46a7bb62917552af7e3a
Publikováno v:
BMC Bioinformatics, Vol 19, Iss 1, Pp 1-13 (2018)
Abstract Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib. However, the sensitivity varies for less common a
Externí odkaz:
https://doaj.org/article/f7027bd88c0c4fce9acdfc604defb23a
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract Metastatic non-small-cell lung cancer (NSCLC) with activating EGFR mutations responds very well to first and second generation tyrosine-kinase inhibitors (TKI) including gefitinib, erlotinib and afatinib. Unfortunately, drug resistance will
Externí odkaz:
https://doaj.org/article/48baaceb101f44bbbb0e692bec36675e
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Background: The fluoropyrimidine anticancer drug, especially 5- fluorouracil (5-FU) and its prodrug capecitabine are still being the backbone of chemotherapeutic regimens for colorectal cancer. Dihydropyrimidine dehydrogenase (DPD) is the crucial enz
Externí odkaz:
https://doaj.org/article/09eda661f1894a56ae53451d6b46d591
Publikováno v:
The Lancet. 401:878-879